Abbreviated Dual Antiplatelet Therapy (DAPT) Regimens Across the Entire Spectrum of Bleeding Risk According to the PRECISE-HBR Score
Authors' conclusion
The PRECISE-HBR score identified patients at increased risk for both bleeding and ischemic events who seemed to derive greater benefit from 1-month DAPT after stent implantation.
Study context
- Population
- High-bleeding risk (HBR) patients treated with cobalt-chromium everolimus-eluting stents who discontinued DAPT at 1 month (XIENCE 28 USA/Global) or 3 months (XIENCE 90)
- Participants
- 3,364 patients · 3 single-arm studies
- Comparison
- 1-month vs 3-month DAPT across PRECISE-HBR score categories
- Score ≤22n = 359
- Score 23-26n = 744
- Score ≥27n = 2,261
Methodological detailsXIENCE Short DAPT program, international, propensity score stratification
- XIENCE Short DAPT program
- International
- Propensity score stratification
Pooled result
As reported in the abstract
BARC type 3-5 bleeding, 1- vs 3-month DAPT, by PRECISE-HBR score · 1 to 12 months
1-month DAPT vs 3-month DAPTHazard ratio (95% CI)
Score ≥27
0.59(0.39–0.88)
Score <27
2.31(0.89–5.99)
Further pooled results
BARC type 3-5 bleeding and death or MI by PRECISE-HBR category
BARC 3-5 bleeding
Death or MI
Ischemic risk, 1- vs 3-month DAPT
- Similar between 1- and 3-month DAPT, irrespective of PRECISE-HBR score
- P for interaction = 0.40
Original publication
Abbreviated DAPT Regimens Across the Entire Spectrum of Bleeding Risk According to the PRECISE-HBR Score. JACC Cardiovasc Interv. Published 13 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it